Trial Profile
A multi-centre, multinational, randomized, double-blind, placebo controlled, proof of concept trial to assess the effects of a subject-optimized dose of UK-369,003 on exercise capacity in subjects with chronic obstructive pulmonary disease
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2016
Price :
$35
*
At a glance
- Drugs Gisadenafil (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- 29 Aug 2006 Status change
- 24 Dec 2005 New trial record.